Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARG | Q86W56 | 1/20 | 0.69 |
| ▸ | LMNA | P02545 | 1/20 | 0.60 |
| ▸ | TP53 | P04637 | 1/20 | 0.60 |
| ▸ | HBB | P68871 | 1/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.60 |
| ▸ | ENTPD1 | P49961 | 1/20 | 0.55 |
| ▸ | TRPM2 | O94759 | 1/20 | 0.55 |
| ▸ | P2RY1 | P47900 | 2/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29413068 | 0.89 | LMNA (0.69) | LMNATP53HBBSMN1; SMN2ENTPD1 | |
| SCHEMBL15456809 | 0.89 | LMNA (0.69) | LMNATP53HBBSMN1; SMN2ENTPD1 | |
| SCHEMBL15245119 | 0.89 | LMNA (0.69) | LMNATP53HBBSMN1; SMN2ENTPD1 | |
| SCHEMBL29810829 | 0.88 | LMNA (0.70) | LMNATP53HBBSMN1; SMN2ENTPD1 | |
| SCHEMBL14853626 | 0.87 | LMNA (0.67) | LMNATP53HBBSMN1; SMN2ENTPD1 | |
| SCHEMBL15305337 | 0.84 | SMN1; SMN2 (0.75) | LMNATP53HBBSMN1; SMN2ENTPD1 | |
| SCHEMBL16543524 | 0.84 | SMN1; SMN2 (0.75) | LMNATP53HBBSMN1; SMN2ENTPD1 | |
| SCHEMBL29810834 | 0.84 | SMN1; SMN2 (0.75) | LMNATP53HBBSMN1; SMN2ENTPD1 | |
| SCHEMBL15721814 | 0.82 | ENTPD1 (0.61) | LMNATP53HBBSMN1; SMN2ENTPD1 | |
| Adenosine Diphosphate (Hydroxymethyl)Pyrrolidinediol SCHEMBL14613252 | 0.82 | PARG (1.00) | PARGSMN1; SMN2TRPM2P2RY1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070032496-A1 | Compounds for the Treatment of Neurodegeneration and Stroke | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS | 2007-02-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070032496-A1 | Compounds for the Treatment of Neurodegeneration and Stroke | PARP1, PARP12, PARP11 | PARG 12/4885LMNA 558/4885TP53 2048/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.